Related Experiment Video
Updated: Jun 8, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
[Evaluation of a selective strategy for glycoprotein IIb/IIIa inhibitors administration in non-ST segment elevation
J-L Georges1, C Charbonnel, R Convers-Domart
1Service de cardiologie, centre hospitalier de Versailles, hôpital André-Mignot, 177, rue de Versailles, 78150 Le Chesnay, France. jgeorges@ch-versailles.fr
Insights
A selective strategy for glycoprotein IIb/IIIa inhibitors in non ST-segment elevation acute coronary syndrome is safe and effective. This approach may be considered for high-risk patients without compromising outcomes in intermediate-risk individuals.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Context:
- Non-ST-segment elevation acute coronary syndrome (NSTE-ACS) management.
- Glycoprotein IIb/IIIa inhibitors are potent antiplatelet agents.
- Optimizing their use in NSTE-ACS is crucial for patient outcomes.
Purpose:
- To evaluate the impact of a selective administration strategy for glycoprotein IIb/IIIa inhibitors in NSTE-ACS patients.
- To assess the safety and efficacy of this selective approach compared to broader use.
Summary:
- A prospective study of 331 NSTE-ACS patients identified criteria for selective glycoprotein IIb/IIIa inhibitor use (e.g., ST elevation, ischemic recurrence, high TIMI risk score).
- Overall use was 16%; 66% of eligible patients received treatment.
- Eligible but untreated patients often had bleeding risks or unfavorable risk-benefit ratios.
Impact:
- The selective strategy was successfully applied in 98% of cases.
- Cardiovascular events and mortality rates were low, with no evidence of harm in intermediate-risk patients.
- This approach may allow for judicious use of glycoprotein IIb/IIIa inhibitors in NSTE-ACS, reserving them for very high-risk situations.
Aims:
We evaluated the impact of a selective strategy for glycoprotein IIb/IIIa inhibitors administration in non ST-segment elevation acute coronary syndrome.
Patients And Method:
Between February 1st, 2007, and February 1st, 2009, 331 consecutive patients were prospectively included in the study. Criteria for upstream glycoprotein IIb/IIIa inhibitors administration were as follows: transient ST elevation greater than 1mm, ST-segment depression greater than 2mm, ischemic recurrence, TIMI risk score greater than 5. Global mortality and cardiovascular outcomes were assessed at Day 7 and Day 30.
Results:
The overall use of glycoprotein IIb/IIIa inhibitors was 16%. The procedure was successfully applied in 98%. Compared with non eligible patients (group 1, n = 254), eligible patients (group 2, n = 77) had a higher risk profile, median age: 73 versus 66, p < 0.01, TIMI risk score: 4 versus 3, p < 0.001. Eligible patients (66%) actually received the treatment. Among the 26 eligible but untreated patients, 19% had major bleeding risk, 34% had an unfavourable risk-benefit ratio and 34% were not suitable for an invasive strategy. Cardiovascular events occurred in 5.1% at Day 7 (Group 1, 1.6%), and 6.0% at Day 30 (group 1, 2.4%). Overall mortality at Day 30 was 1.2% (0.4% in Group 1).
Conclusion:
A strategy for glycoprotein IIb/IIIa inhibitors administration in non ST-segment elevation acute coronary syndrome restricted to 4 very high risk situations may be considered, without evidence for a loss of chance in intermediate risk patients, untreated although eligible for treatment according to the current guidelines.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:26Acute Coronary Syndrome V: Nursing Management
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Acute Coronary Syndrome I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations